Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 580-586

  Palanichamy, Arumugam ^a   Jahn, Sarah ^a   Nickles, Dorothee ^a   Derstine, Mia ^a   Abounasr, Aya ^a   Hauser, Stephen L ^a   Baranzini, Sergio E ^a   Leppert, David ^b   Von Büdingen, H Christian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; RITUXIMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL DEPLETION; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD3; B-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTE SUBSETS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84904266641     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400118     Document Type: Article

References (37)

1. Bar-Or, A., P. A. Calabresi, D. Arnold, C. Markowitz, S. Shafer, L. H. Kasper, E. Waubant, S. Gazda, R. J. Fox, M. Panzara, et al. 2008. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. [Published erratum appears in 2008. Ann. Neurol. 63: 803.] Ann. Neurol. 63: 395-400. (Pubitemid 351499869)
2. Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al HERMES Trial Group. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676-688. (Pubitemid 351240747)
3. Maloney, D. G., T. M. Liles, D. K. Czerwinski, C. Waldichuk, J. Rosenberg, A. Grillo-Lopez, and R. Levy. 1994. Phase I clinical trial using escalating singledose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466. (Pubitemid 24317376)
4. Leandro, M. J., G. Cambridge, M. R. Ehrenstein, and J. C. Edwards. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54: 613-620. (Pubitemid 43228639)
5. Hauser, S. L., D. Li, P. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, A. Sauter, D. Leppert, D. Masterman, J. Tinbergen, and L. Kappos. 2013. Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS). Neurology 80: S31.004.
6. Hultin, L. E., M. A. Hausner, P. M. Hultin, and J. V. Giorgi. 1993. CD20 (pan- B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14: 196-204. (Pubitemid 23042743)
7. Henry, C., A. Ramadan, N. Montcuquet, J. R. Pallandre, P. Mercier-Letondal, M. Deschamps, P. Tiberghien, C. Ferrand, and E. Robinet. 2010. CD3+CD20+ cells may be an artifact of flow cytometry: comment on the article by Wilk et al. Arthritis Rheum. 62: 2561-2563, author reply 2563-2565.
8. Wilk, E., T. Witte, N. Marquardt, T. Horvath, K. Kalippke, K. Scholz, N. Wilke, R. E. Schmidt, and R. Jacobs. 2009. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 60: 3563-3571.
9. Eggleton, P., E. Bremer, J. M. Tarr, M. de Bruyn, W. Helfrich, A. Kendall, R. C. Haigh, N. J. Viner, and P. G. Winyard. 2011. Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res. Ther. 13: R208.
10. Kauffmann, A., R. Gentleman, and W. Huber. 2009. arrayQualityMetrics - a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416.
11. Carvalho, B. S., and R. A. Irizarry. 2010. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26: 2363-2367.
12. Oksenberg, J. R., S. E. Baranzini, S. Sawcer, and S. L. Hauser. 2008. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9: 516-526. (Pubitemid 351861542)
13. Simmons, S. B., E. R. Pierson, S. Y. Lee, and J. M. Goverman. 2013. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 34: 410-422.
14. Sospedra, M., and R. Martin. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747. (Pubitemid 40563183)
15. Babbe, H., A. Roers, A. Waisman, H. Lassmann, N. Goebels, R. Hohlfeld, M. Friese, R. Schröder, M. Deckert, S. Schmidt, et al. 2000. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192: 393-404. (Pubitemid 30629164)
16. Hauser, S. L., A. K. Bhan, F. Gilles, M. Kemp, C. Kerr, and H. L. Weiner. 1986. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann. Neurol. 19: 578-587. (Pubitemid 16085192)
17. Tsuchida, T., K. C. Parker, R. V. Turner, H. F. McFarland, J. E. Coligan, and W. E. Biddison. 1994. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc. Natl. Acad. Sci. USA 91: 10859-10863.
18. Crawford, M. P., S. X. Yan, S. B. Ortega, R. S. Mehta, R. E. Hewitt, D. A. Price, P. Stastny, D. C. Douek, R. A. Koup, M. K. Racke, and N. J. Karandikar. 2004. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103: 4222-4231. (Pubitemid 38685367)
19. Sun, D., J. N. Whitaker, Z. Huang, D. Liu, C. Coleclough, H. Wekerle, and C. S. Raine. 2001. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166: 7579-7587. (Pubitemid 32525639)
20. Sasaki, K., A. Bean, S. Shah, E. Schutten, P. G. Huseby, B. Peters, Z. T. Shen, V. Vanguri, D. Liggitt, and E. S. Huseby. 2014. Relapsing-remitting central nervous system autoimmunity mediated by GFAP-specific CD8 T cells. J. Immunol. 192: 3029-3042.
21. Kappos, L., D. Li, P. A. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, M. Yin, D. Leppert, R. Glanzman, J. Tinbergen, and S. L. Hauser. 2011. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779-1787.
22. Castillo, J., C. Milani, and D. Mendez-Allwood. 2009. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin. Investig. Drugs 18: 491-500.
23. Herbst, R., Y. Wang, S. Gallagher, N. Mittereder, E. Kuta, M. Damschroder, R. Woods, D. C. Rowe, L. Cheng, K. Cook, et al. 2010. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. [Published erratum appears in 2011 J. Pharmacol. Exp. Ther. 336: 294.] J. Pharmacol. Exp. Ther. 335: 213-222.
24. Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis. Available at: http:// clinicaltrials.gov/ct2/show/NCT01585766. Accessed May 14, 2014.
25. Cross, A. H., J. L. Stark, J. Lauber, M. J. Ramsbottom, and J. A. Lyons. 2006. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180: 63-70. (Pubitemid 44767709)
26. Piccio, L., R. T. Naismith, K. Trinkaus, R. S. Klein, B. J. Parks, J. A. Lyons, and A. H. Cross. 2010. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67: 707-714.
27. Bar-Or, A., L. Fawaz, B. Fan, P. J. Darlington, A. Rieger, C. Ghorayeb, P. A. Calabresi, E. Waubant, S. L. Hauser, J. Zhang, and C. H. Smith. 2010. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67: 452-461.
28. Monson, N. L., P. Cravens, R. Hussain, C. T. Harp, M. Cummings, M. de Pilar Martin, L. H. Ben, J. Do, J. A. Lyons, A. Lovette-Racke, et al. 2011. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS ONE 6: e17103.
29. Weber, M. S., T. Prod'homme, J. C. Patarroyo, N. Molnarfi, T. Karnezis, K. Lehmann-Horn, D. M. Danilenko, J. Eastham-Anderson, A. J. Slavin, C. Linington, et al. 2010. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann. Neurol. 68: 369-383.
30. Xu, H., M. S. Williams, and L. M. Spain. 2006. Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for MS4a4B, a CD20 homolog in Th1 T cells. Blood 107: 2400-2408. (Pubitemid 43345560)
31. Yan, Y., Z. Li, G. X. Zhang, M. S. Williams, G. B. Carey, J. Zhang, A. Rostami, and H. Xu. 2013. Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis. Apoptosis 18: 1106-1119.
32. Cragg, M. S., C. A. Walshe, A. O. Ivanov, and M. J. Glennie. 2005. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8: 140-174.
33. Walshe, C. A., S. A. Beers, R. R. French, C. H. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg. 2008. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J. Biol. Chem. 283: 16971-16984.
34. Kuijpers, T. W., R. J. Bende, P. A. Baars, A. Grummels, I. A. Derks, K. M. Dolman, T. Beaumont, T. F. Tedder, C. J. van Noesel, E. Eldering, and R. A. van Lier. 2010. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. 120: 214-222.
35. Hachiya, Y., A. Uruha, E. Kasai-Yoshida, K. Shimoda, I. Satoh-Shirai, S. Kumada, E. Kurihara, K. Suzuki, A. Ohba, S. Hamano, and H. Sakuma. 2013. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J. Neuroimmunol. 265: 128-130.
36. Huang, H., C. Benoist, and D. Mathis. 2010. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc. Natl. Acad. Sci. USA 107: 4658-4663.
37. Wei, C., J. Anolik, A. Cappione, B. Zheng, A. Pugh-Bernard, J. Brooks, E. H. Lee, E. C. Milner, and I. Sanz. 2007. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J. Immunol. 178: 6624-6633. (Pubitemid 46717447)